Antonio Lambiase - MolMed S Insider

MolMed S p A -- Germany Stock  

EUR 0.43  0.02  4.88%

Director Clinical Development

Dr. Antonio Lambiase serves as Director of Clinical Development at Molecular Medicine S.p.A. since March 2007. He previously worked for over 15 years at Roche in the areas of oncology and hematology as Medical Responsible for Clinical Development of several biological and molecular targeted compounds, including cancer bio therapeutics, hematopoietic growth factors, and therapeutic monoclonal antibodies and antiangiogenesis agents. Before that, he spent three years as Research Fellow at the Medical Oncology Unit of National Cancer Institute of Milan. He gained a degree in Medicine from Universita degli Studi di Napoli Federico II and a Doctorate of Medicine in Medicine from Universita degli Studi di Napoli Federico II.
Age: 55  Director Since 2007  Ph.D    

Management Efficiency

The company has return on total asset (ROA) of (18.1) % which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (61.21) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Entity Summary

MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. and employs 23 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add MolMed S p A to your portfolio

Top Management

MolMed S p Leadership Team
Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance

MolMed S Performance Indicators
Return On Equity(61.21) %
Return On Asset(18.1) %
Current Valuation195.6 M
Price to Earning(13.82) times
Price to Book11.53 times
Price to Sales9.28 times
Revenue22.42 M
Gross Profit1000 K
EBITDA(10.6 M)
Net Income(12.02 M)